China’s National Medical Products Administration updated Good Clinical Practice rules that will take effect in September, emphasizing clinical trial data governance, transparency, and participant privacy. The revised guideline, first published June 8 and updated since 2020, also reiterates that trials should comply with the Declaration of Helsinki and related ethics requirements. For CROs and sponsors, the update introduces clearer expectations for how paper and electronic trial materials must be recorded, processed, stored, and made traceable. It also calls out risk-appropriate data collection and the protection of personal information, aligning trial operations more tightly with international ethical principles. The practical impact is immediate for trial planning, data systems, vendor documentation, and audit readiness for both domestic and multinational programs operating in China’s GCP framework.